Predicting non-adherence in patients with familial hypercholesterolemia

European Journal of Clinical Pharmacology

Volumn 70, Issue 4, 2014, Pages 391-397

  Galema Boers, J M H ^a   Lenzen, M J ^a   Van Domburg, R T ^a   Roeters Van Lennep, J ^a   Van Bruchem Van De Scheur, G G ^b   Sijbrands, E J ^a   Langendonk, J G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ROTTERDAM UNIVERSITY OF APPLIED SCIENCES   (Netherlands)

Author keywords

Adherence; Compliance; Coronary heart disease; Familial hypercholesterolemia; Prediction model; Statins

Indexed keywords

APOLIPOPROTEIN B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

ADULT; ARTICLE; AVERSION; CALIBRATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL STUDY; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE TITRATION; DRUG MEGADOSE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FIRST DEGREE RELATIVE; GENE MUTATION; GROUPS BY AGE; HEALTH SURVEY; HETEROZYGOTE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MEDICATION NONADHERENCE; MIDDLE AGED; NETHERLANDS; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; TREATMENT DURATION; UNIVERSITY HOSPITAL; UNSPECIFIED SIDE EFFECT; XANTHOMA; YOUNG ADULT; ADOLESCENT; BLOOD; COMPLICATION; CORONARY DISEASE; HYPERLIPOPROTEINEMIA TYPE II;

ADOLESCENT; ADULT; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MEDICATION ADHERENCE; MIDDLE AGED; YOUNG ADULT;

EID: 84896493096     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1640-3     Document Type: Article

References (38)

1. Stone NJ, Levy RI, Fredrickson DS, Verter J (1974) Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 49(3):476-488
2. Austin MA, Hutter CM, Zimmern RL, Humphries SE (2004) Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol 160(5):421-429 (Pubitemid 39166974)
3. Civeira F, International Panel on Management of Familial H (2004) Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 173(1):55-68
4. Jansen ACM, van Aalst-Cohen ES, Tanck MW, Trip MD, Lansberg PJ, Liem AH, Roeters van Lennep HWO, Sijbrands EJG, Kastelein JJP (2004) The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 256(6):482-490. doi:10.1111/j.1365-2796.2004.01405.x (Pubitemid 39577582)
5. Scientific Steering Committee on behalf of the Simon Broome Register Group (1999) Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 142(1):105-112
6. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF (2001) Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357(9256):577-581 (Pubitemid 32179609)
7. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, Heeringa J, Witteman JC, Lansberg PJ, Kastelein JJ, Sijbrands EJ (2008) Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. Br Med J 337:a2423
8. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ (2012) Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 380(9841):565-571. doi:10.1016/S0140-6736(12)61190-8
9. Frisinghelli A, Mafrici A (2007) Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review. Clin Drug Investig 27(9):591-604 (Pubitemid 47295718)
10. Osterberg L, Blaschke T (2005) Adherence to Medication. N Engl J Med 353(5):487-497. doi:10.1056/NEJMra050100 (Pubitemid 41127293)
11. Perreault S, Dragomir A, Blais L, Bérard A, Lalonde L, White M, Pilon D (2009) Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol 65(10):1013-1024. doi:10.1007/s00228-009-0673-0
12. De Geest S, Sabate E (2003) Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs 2(4):323 (Pubitemid 37518223)
13. Garner JB (2010) Problems of Nonadherence in Cardiology and Proposals to Improve Outcomes. Am J Cardiol 105(10):1495-1501. doi:10.1016/j.amjcard.2009.12. 077
14. Naderi SH, Bestwick JP, Wald DS (2012) Adherence to Drugs That Prevent Cardiovascular Disease: Meta-analysis on 376,162 Patients. Am J Med 125(9):882-887.e881. doi:10.1016/j.amjmed.2011.12.013
15. Mann DM, Woodward M, Muntner P, Falzon L, Kronish I (2010) Predictors of nonadherence to statins: a systematic review and metaanalysis. Ann Pharmacother 44(9):1410-1421
16. Briesacher BA, Gurwitz JH, Soumerai SB (2007) Patients at-risk for cost-related medication nonadherence: a review of the literature. J Gen Intern Med 22(6):864-871 (Pubitemid 46763978)
17. Lemstra M, Blackburn D, Crawley A, Fung R (2012) Proportion and Risk Indicators of Nonadherence to Statin Therapy: A Meta-analysis. Can J Cardiol 28(5):574-580. doi:10.1016/j.cjca.2012.05.007
18. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M (2008) Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. Br Med J 336(7653):1114-1117 (Pubitemid 351731741)
19. Bouchard MH, Dragomir A, Blais L, Berard A, Pilon D, Perreault S (2007) Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol 63(6):698-708, 697-622
20. Rubak S, Sandboek A, Lauritzen T, Christensen B (2005) Motivational Interviewing; a systematic review and meta-analysis. Br J Gen Pract 4:305-312 (Pubitemid 40520908)
21. Hartley M, Repede E (2011) Nurse Practitioner Communication and Treatment Adherence in Hypertensive Patients. J Nurs Pract 7:654-659
22. van Onzenoort H, Verberk W, Kroon A, Kessels A, Neef C, van der Kuy P, de Leeuw P (2012) Electronic Monitoring of Adherence, Treatment of Hypertension and Blood Pressure Control. Am J Hypertens 25(1):54-59
23. Sol BG, van der Graaf Y, van der Bijl JJ, Goessens NB, Visseren FL (2006) Self-efficacy in patients with clinical manifestations of vascular diseases. Patient Educ Couns 61(3):443-448 (Pubitemid 43767444)
24. Marks R, Allegrante JP, Lorig K (2005) A review and synthesis of research evidence for self-efficacy-enhancing interventions for reducing chronic disability: implications for health education practice (part II). Health Promot Pract 6(2):148-156
25. van de Laar KE, van der Bijl JJ (2001) Strategies enhancing self-efficacy in diabetes education: a review. Sch Inq Nurs Pract 15(3):235-248
26. van Aalst-Cohen ES, Jansen AC, Tanck MW, Defesche JC, Trip MD, Lansberg PJ, Stalenhoef AF, Kastelein JJ (2006) Diagnosing familial hypercholesterolaemia: the relevance of genetic testing. Eur Heart J 27(18):2240-2246 (Pubitemid 44412840)
27. Horne R, Weinman J (2002) Self-regulation and self-management in asthma; exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health 17:17-32
28. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Kjeldsen SE, Erdine S, Narkiewicz K, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Cifkova R, Dominiczak A, Fagard R, Heagerty AM, Laurent S, Lindholm LH, Mancia G, Manolis A, Nilsson PM, Redon J, Schmieder RE, Struijker-Boudier HA, Viigimaa M, Filippatos G, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Kiowski W, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Viigimaa M, Waeber B, Williams B, Zamorano JLSH, The task force for the management of arterial hypertension of the European Society of Hypertension Society of C, The task force for the management of arterial hypertension of the European Society of C (2007) 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28(12):1462-1536
29. Concato J, Peduzzi P, Holford TR, Feinstein AR (1995) Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. J Clin Epidemiol 48(12):1495-1501 (Pubitemid 26035532)
30. Pijlman AH, Huijgen R, Verhagen SN, Imholz BP, Liem AH, Kastelein JJ, Abbink EJ, Stalenhoef AF, Visseren FL (2010) Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 209(1):189-194
31. Bates TR, Connaughton VM, Watts GF (2009) Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother 10(18):2973-2985. doi:10.1517/14656560903376186
32. Rasmussen JN, Chong A, Alter DA (2007) Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 297(2):177-186. doi:10.1001/jama.297.2.177 (Pubitemid 46089734)
33. European Association for Cardiovascular P, Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D, Guidelines ESCCfP, Committees (2011) ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32(14):1769-1818. doi:10.1093/eurheartj/ehr158
34. Hollman G, Olsson AG, Ek AC (2006) Disease knowledge and adherence to treatment in patients with familial hypercholesterolemia. J Cardiovasc Nurs 21(2):103-108
35. Weinstein ND, Sandman PM (1992) A model of the precaution adoption process: evidence from home radon testing. Health Psychol 11(3):170-180
36. Law M, Rudnicka AR (2006) Statin safety: a systematic review. Am J Cardiol 97(8A):52C-60C
37. Nieuwenhuis MM, Jaarsma T, van Veldhuisen DJ, van der Wal MH (2012) Self-reported versus 'true' adherence in heart failure patients: a study using the Medication Event Monitoring System. Neth Heart J 20(7-8):313-319
38. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, Christian J, Maldonado T, Duran D, Kaplan AH, Wenger NS (2001) A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 134(10):968-977 (Pubitemid 32466236)